Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice

International Immunopharmacology

Volumn 9, Issue 7-8, 2009, Pages 900-909

  Le, Hanh K ^a   Graham, Laura ^b   Cha, Esther ^a   Morales, Johanna K ^a   Manjili, Masoud H ^a   Bear, Harry D ^a,b  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Massey Cancer Center   (United States)

Author keywords

4T1; Gemcitabine; Immunosuppression; Mammary carcinoma; Myeloid derived suppressor cells; T cell

Indexed keywords

CYCLOPHOSPHAMIDE; GAMMA INTERFERON; GEMCITABINE; TUMOR ANTIGEN;

ADOPTIVE IMMUNOTHERAPY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CD8+ T LYMPHOCYTE; CELL EXPANSION; CELL FUNCTION; CELL ISOLATION; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXICITY; DRUG MECHANISM; FEMALE; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IMMUNOSUPPRESSIVE TREATMENT; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; SPLENOMEGALY; SUPPRESSOR CELL; T LYMPHOCYTE; TUMOR GROWTH; TUMOR VOLUME;

ANIMALS; ANTIGENS, NEOPLASM; CARCINOMA; CELL GROWTH PROCESSES; DEOXYCYTIDINE; DRUG THERAPY; FEMALE; IMMUNE TOLERANCE; IMMUNOTHERAPY, ADOPTIVE; LYMPHOCYTE ACTIVATION; MAMMARY NEOPLASMS, ANIMAL; MICE; MICE, INBRED BALB C; T-LYMPHOCYTES; TUMOR BURDEN; TUMOR ESCAPE;

EID: 67349133537     PISSN: 15675769     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.intimp.2009.03.015     Document Type: Article

References (47)

1. Frey A.B. Myeloid suppressor cells regulate the adaptive immune response to cancer. J Clin Invest 116 (2006) 2587-2590
2. Talmadge J.E. Pathways mediating the expansion and immunosuppressive activity of myeloid-derived suppressor cells and their relevance to cancer therapy. Clin Cancer Res 13 (2007) 5243-5248
3. Gallina G., Dolcetti L., Serafini P., Santo C.D., Marigo I., Colombo M.P., et al. Tumors induce a subset of inflammatory monocytes with immunosuppressive activity on CD8+ T cells. J Clin Invest 116 (2006) 2777-2790
4. Serafini P., Borrello I., and Bronte V. Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 16 (2006) 53-65
5. Zea A.H., Rodriguez P.C., Atkins M.B., Hernandez C., Signoretti S., Zabaleta J., et al. Arginase-producing myeloid suppressor cells in renal cell carcinoma patients: a mechanism of tumor evasion. Cancer Res 65 (2005) 3044-3048
6. Kusmartsev S., and Gabrilovich D.I. STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J Immunol 174 (2005) 4880-4891
7. Kusmartsev S., and Gabrilovich D.I. Role of immature myeloid cells in mechanisms of immune evasion in cancer. Cancer Immunol Immunother 55 (2006) 237-245
8. Apolloni E., Bronte V., Mazzoni A., Serafini P., Cabrelle A., Segal D.M., et al. Immortalized myeloid suppressor cells trigger apoptosis in antigen-activated T lymphocytes. J Immunol 165 (2000) 6723-6730
9. Mazzoni A., Bronte V., Visintin A., Spitzer J.H., Apolloni E., Serafini P., et al. Myeloid suppressor lines inhibit T cell responses by an NO-dependent mechanism. J Immunol 168 (2002) 689-695
10. Kusmartsev S., Nefedova Y., Yoder D., and Gabrilovich D.I. Antigen-specific inhibition of CD8+ T cell response by immature myeloid cells in cancer is mediated by reactive oxygen species. J Immunol 172 (2004) 989-999
11. Sinha P., Clements V.K., Bunt S.K., Albelda S.M., and Ostrand-Rosenberg S. Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol 179 (2007) 977-983
12. Mills C.D., Kincaid K., Alt J.M., Heilman M.J., and Hill A.M. M-1/M-2 macrophages and the Th1/Th2 paradigm. J Immunol 164 (2000) 6166-6173
13. Huang B., Pan P.Y., Li Q., Sato A.I., Levy D.E., Bromberg J., et al. Gr-1+CD115+ immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 66 (2006) 1123-1131
14. Bunt S.K., Yang L., Sinha P., Clements V.K., Leips J., and Ostrand-Rosenberg S. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res 67 20 (2007 Oct 15) 10019-10026
15. Habibi M., Kmieciak M., Graham L., Morales J.K., Bear H.D., and Manjili M.H. Radiofrequency thermal ablation of breast tumors combined with intralesional administration of IL-7 and IL-15 augments anti-tumor immune responses and inhibits tumor development and metastasis. Breast Cancer Res Treat (Apr 20 2008) [Electronic publication ahead of print]
16. Diaz-Montero C.M., Salem M.L., Nishimura M.I., Garrett-Mayer E., Cole D.J., and Montero A.J. Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy. Cancer Immunol Immunother 57 2 (2008) 271-280
17. Suzuki E., Kapoor V., Jassar A.S., Kaiser L.R., and Albelda S.M. Gemcitabine selectively eliminates splenic gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity. Clin Cancer Res 11 (2005) 6713-6721
18. Hui Y.F., and Reitz J. Gemcitabine: a cytidine analogue active against solid tumors. Am J Health Syst Pharm 54 (1997) 162-170
19. Shipley L.A., Brown T.J., Cornpropst J.D., Hamilton M., Daniels W.D., and Culp H.W. Metabolism and disposition of gemcitabine, and oncolytic deoxycytidine analog, in mice, rats, and dogs. Drug Metab Dispos 20 (1992) 849-855
20. Gabrilovich D.I., Velders M.P., Sotomayor E.M., and Kast W.M. Mechanism of immune dysfunction in cancer mediated by immature gr-1+ myeloid cells. J Immunol 166 (2001) 5398-5406
21. Nagaraj S., Gupta K., Pisarev V., Kinarsky L., Sherman S., Kang L., et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med 13 (2007) 828-835
22. Ko H.J., Kim Y.J., Kim Y.S., Chang W.S., Ko S.Y., Chang S.Y., et al. A combination of chemoimmunotherapies can efficiently break self-tolerance and induce antitumor immunity in a tolerogenic murine tumor model. Cancer Res 67 (2007) 7477-7486
23. Smith J.A., Brown J., Martin M.C., Ramondetta L.M., and Wolf J.K. An in vitro study of the inhibitory activity of gemcitabine and platinum agents in human endometrial carcinoma cell lines. Gynecol Oncol 92 (2004) 314-319
24. Nowak A.K., Robinson B.W., and Lake R.A. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 63 (2003) 4490-4496
25. Plate J.M., Plate A.E., Shott S., Bograd S., and Harris J.E. Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas. Cancer Immunol Immunother 54 (2005) 915-925
26. Seung L.P., Rowley D.A., Dubey P., and Schreiber H. Synergy between T-cell immunity and inhibition of paracrine stimulation causes tumor rejection. Proc Natl Acad Sci U S A 92 (1995) 6254-6258
27. Kusmartsev S., Cheng F., Yu B., Nefedova Y., Sotomayor E., Lush R., et al. All-trans-retinoic acid eliminates immature myeloid cells from tumor-bearing mice and improves the effect of vaccination. Cancer Res 63 (2003) 4441-4449
28. Sinha P., Clements V.K., and Ostrand-Rosenberg S. Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol 174 (2005) 636-645
29. Broomfield S., Currie A., van der Most R.G., Brown M., van Bruggen I., Robinson B.W.S., et al. Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy. Cancer Res 65 (2005) 7580-7584
30. Nowak A.K., Lake R.A., Marzo A.L., Scott B., Heath W.R., Collins E.J., et al. Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol 170 (2003) 4905-4913
31. Nowak A.K., Robinson B.W., and Lake R.A. Gemcitabine exerts a selective effect on the humoral immune response: implications for combination chemo-immunotherapy. Cancer Res 62 (2002) 2353-2358
32. Suzuki E., Sun J., Kapoor V., Jassar A.S., and Albelda S.M. Gemcitabine has significant immunomodulatory activity in murine models independent of its cytotoxic effects. Cancer Biology and Therapy 6 6 (2007) 880-885
33. Bronte V., and Zanovello P. Regulation of immune responses by l-arginine metabolism. Nat Rev Immunol 5 8 (2005) 641-654
34. Ochoa A.C., Zea A.H., Hernandez C., and Rodriguez P.C. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res 13 2 (2007) 721s-726s
35. Morales J., Kmieciak M., Graham L., Feldmesser M., Bear H., and Manjili M.H. Adoptive transfer of HER2/neu-specific T cells expanded with alternating gamma chain cytokines mediate tumor regression when combined with the depletion of myeloid-derived suppressor cells. Cancer Immunol Immunother (2008) [Electronic publication ahead of print]
36. Sinha P., Okoro C., Foell D., Freeze H., Ostrand-Rosenberg S., and Srikrishna G. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol 181 (2008) 4666-4675
37. Kmieciak M., Knutson K.L., Dumur C.I., and Manjili M.H. Her-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses. Eur J Immunol 37 (2007) 675-685
38. Beatty G.L., and Paterson Y. IFN-c can promote tumor evasion of the immune system in vivo by down-regulating cellular levels of an endogenous tumor antigen. J Immunol 165 (2000) 5502-5508
39. Merriman R.L., Hertel L.W., Schultz R.M., Houghton P.J., Houghton J.A., Rutherford P.G., et al. Comparison of the antitumor activity of gemcitabine and ara-C in a panel of human breast, colon, lung, and pancreatic xenograft models. Invest New Drugs 14 (1996) 243-247
40. Bergman A.M., Pinedo H.M., and Peters G.J. Determinants of resistance to 2′,2′-difluorodeoxycytidine (gemcitabine). Drug Resist Updat 5 (2002) 19-33
41. Al-Madhoun A.S., Van der Wilt C.L., Loves W.J.P., Padron J.M., Eriksson S., Talianidis I., et al. Detection of an alternatively spliced form of deoxycytidine kinase mRNA in the 2′-2′-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell lime AG6000. Biochem Pharmacol 68 (2004) 601-609
42. Sebastiani V., Ricci F., Rubio-Viquiera B., Kulesza P., Yeo C.J., Hidalgo M., et al. Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival. Clin Cancer Res 12 8 (2006) 2492-2497
43. Wang L., Munch-Petersen B., Herrstrom Sjoberg A., Hellman U., Bergman T., Jörnvall H., et al. Human thymidine kinase 2: molecular cloning and characterisation of the enzyme activity with antiviral and cytostatic nucleoside substrates. FEBS Lett 443 (1999) 170-174
44. Bouffard D.Y., Laliberte J., and Momparler R.L. Kinetic studies on 2′,2′-difluorodeoxycytidine (gemcitabine) with purified human deoxycytidine kinase and cytidine deaminase. Biochem Pharmacol 45 (1993) 1857-1861
45. Bear H.D. Tumor-specific suppressor T-cells which inhibit the in vitro generation of cytolytic T cells from immune and early tumor-bearing host spleens. Cancer Res 46 (1986) 1805
46. Hoover S.K., Barrett S.K., Turk T.M.T., Lee T.-C., and Bear H.D. Cyclophosphamide and abrogation of tumor-induced suppressor T cell activity. Cancer Immunol. Immunother 31 (1990) 121
47. Tuttle T.M., Fleming M.F., Hogg P.S., Inge T.H., and Bear H.D. Low-dose cyclophosphamide overcomes metastasis-induced immunosuppression. Ann Surg Oncol 1 (1994) 53